NXP-800

Nov. 25, 2025 -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Uncita-Broceta, MPharm, MSc, PhD (Professor of Chemistry, University of Edinburgh) who will join Company management to discuss the NXP900 development program. The discussion will focus on key NXP900 preclinical and clinical data to date and the strategy for the monotherapy and combination components of the NXP900 Phase 1b clinical program. Dr. Alexander Spira is the Chief Scientific Officer of NEXT Oncology. He serves as Chair of the US Oncology Research Executive Committee and is a member of US Oncology National Policy Board Executive Committee. He is also a faculty member at Johns Hopkins School of Medicine, where he is an Assistant Professor of Oncology. He has authored many important manuscripts in highly prestigious journals such as the New England Journal of Medicine, Journal of Clinical Research, and Clinical Cancer Research, involving innovative new therapies for the treatment of cancer. In addition to his work with NEXT Oncology, Dr. Spira is deeply engaged in advancing targeted cancer treatments through Phase 1 clinical trials. His areas of interest include immunotherapy, personalized medicine, gastrointestinal cancers, thoracic and lung cancers, and sarcomas. Recognized as a “Top Doctor” by both Northern Virginia Magazine and Washingtonian Magazine, Dr. Spira received the prestigious Castle Connolly “America’s Top Doctor” award in 2014. Dr. Spira will continue to serve as the Co-Director, Virginia Cancer Specialists’ Research Institute, and Director of Virginia Cancer Specialists’ Thoracic and Phase I Program. Dr. Spira earned his medical degree from the New York University School of Medicine, completing his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. Dr. Spira also received his PhD from the New York School of Arts and Sciences. Dr. Asier Uncita-Broceta received his PhD in Medicinal Chemistry from the Universidad of Granada (Spain) in 2004 and completed his postdoctoral training in the fields of cell delivery and chemical biology in the School of Chemistry of the University of Edinburgh. He joined the Cancer Research UK Edinburgh Centre as a group leader in 2010, where he established the Innovative Therapeutics Lab in 2010 (first chemistry lab of the Institute). Asier was promoted to Reader in 2015 and Full Professor in 2018. Asier is an Elected Member of the RSE Young Academy of Scotland, Associate Editor of Frontiers in Chemistry and Editorial Board Member of Scientific Reports. He is PI of Edinburgh Drug Discovery and Chemistry Director of the Edinburgh Cancer Discovery Unit. Among his awards highlight the CRUK Pioneer Award 2015, the EPSRC Healthcare Technology Challenge Award 2015 and the RSE/Patrick Neill Medal 2016. NXP900 is a selective orally administered small molecule type 1.5 SRC/YRS1 kinase inhibitor. NXP900’s unique mechanism of action was designed to completely shut-down the YES1/SRC pathway by inhibiting both the catalytic and scaffolding functions of the SRC pathway, while avoiding paradoxical activation of pro-oncogenic signaling, a phenomenon observed with type 1 inhibitors. NXP900 completed a Phase 1a dose escalation study in patients with advanced solid tumors. A Phase 1b single agent dose expansion study is underway in patients with advanced solid tumors with pathogenic mutations. Data from a recently completed drug-drug interaction study support initiation of enrollment in the Phase 1b dose expansion combination arm, anticipated to begin by YE 2025. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's lead drug candidate, NXP900, is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900’s unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and is being evaluated in a Phase 1b program. The Company is also considering next steps for NXP800, an oral small molecule GCN2 activator that has demonstrated anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. The content above comes from the network. if any infringement, please contact us to modify.

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosingNXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapyPoster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlight the emerging clinical profile of NXP900 and provide further support for the biomarker-based patient selection strategyCash runway expected to support the company’s operations into 3Q-2027 Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on advancing the clinical work required to support our ambitious Phase 1b program for NXP900, which recently commenced.” Mr. Bentsur continued, “Our goal for the Phase 1b program is to showcase NXP900's therapeutic potential, both as a single agent and in combination with certain market-leading therapies with the aim of reversing acquired resistance to these drugs. With the Phase 1b monotherapy component already underway, and the expected upcoming initiation of the combination component, we continue to make strides towards achieving this goal." Mr. Bentsur added, "To support and inform the Phase 1b program, we completed the NXP900 Phase 1a dose escalation study and the drug-drug interaction study in healthy volunteers and are pleased with NXP900’s emerging clinical profile, especially with the deep pharmacodynamic response observed at clinically relevant doses.” Mr. Bentsur concluded, “We believe that our cash position and focus on efficient operations will enable us to achieve the key milestones and potential value inflection points for the NXP900 Phase 1b program.” Third Quarter 2025 Financial Results Cash and cash equivalents were $35.4 million as of September 30, 2025, compared to $18.5 million as of December 31, 2024. The increase of $16.9 million in the cash balance as of the end of the third quarter of 2025 is a result primarily of our public offering in February 2025 and the utilization of our At-the-Market facility, partially offset by the operating expenses for the first nine months of 2025. The Company's net loss was $7.5 million for the three months ended September 30, 2025, compared to $4.2 million for the three months ended September 30, 2024, an increase in net loss of $3.4 million. The increase in net loss in the third quarter of 2025 was primarily due to a one-time $2.0 million milestone achievement expense for NXP900 and $0.7 million related to the clinical drug-drug interaction study. The three months ended September 30, 2025 also includes $1.5 million of non-cash stock-based compensation. Research and development expenses, including non-cash stock-based compensation, were $5.8 million for the three months ended September 30, 2025, compared to $2.8 million for the three months ended September 30, 2024, an increase of $3.0 million. General and administrative expenses, including non-cash stock-based compensation, were $2.0 million for the three months ended September 30, 2025, compared to $1.5 million for the three months ended September 30, 2024, an increase of $0.5 million. Interest income was $0.3 million for the three months ended September 30, 2025, compared to $0.2 million for the three months ended September 30, 2024. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's lead program, NXP900, is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and is being evaluated in a Phase 1b program. The Company is also considering next steps for NXP800, an oral small molecule GCN2 activator that has demonstrated anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. For additional information about Nuvectis Pharma please visit: https://nuvectis.com/ Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations and interpretations of data and information available, including but not limited to preclinical and clinical data generated to date for NXP900, the timing and data expectations for the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Furthermore, certain forward-looking statements are based on assumptions regarding future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in our Q2 2025 Form 10-Q and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contact Ron Bentsur Chairman, Chief Executive Officer, and President rbentsur@nuvectis.com Media Relations Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com NUVECTIS PHARMA, INC.BALANCE SHEET(USD in thousands, except per share and share amounts) September 30, December 31, 2025 2024 Assets CURRENT ASSETS Cash and cash equivalents $35,442 $18,533 Other current assets 145 74 TOTAL CURRENT ASSETS 35,587 18,607 TOTAL ASSETS $35,587 $18,607 Liabilities and Shareholders’ Equity CURRENT LIABILITIES Accounts payables $6,439 $2,498 Payable offering costs 75 — Accrued liabilities 65 840 Employee compensation and benefits 4,998 5,556 TOTAL CURRENT LIABILITIES 11,577 8,894 TOTAL LIABILITIES 11,577 8,894 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS’ EQUITY Common Shares, $0.00001 par value – 60,000,000 shares authorized as of September 30, 2025, and December 31, 2024, 25,639,896, and 19,495,683 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively * * Additional paid in capital 116,383 82,958 Accumulated deficit (92,373) (73,245) TOTAL SHAREHOLDERS’ EQUITY 24,010 9,713 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $35,587 $18,607 * Represents an amount lower than $1 USD. NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts) Three Months Ended September 30 Nine Months Ended September 30 2025 2024 2025 2024 OPERATING EXPENSES Research and development $5,774 $2,819 $13,067 $8,422 General and administrative 2,020 1,540 6,890 4,976 OPERATING LOSS (7,794) (4,359) (19,957) (13,398) Finance income 332 206 829 646 NET LOSS $(7,462) $(4,153) $(19,128) $(12,752) EFFECT OF WARRANT MODIFICATION (2,429) — (2,429) — TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $(9,891) $(4,153) $(21,557) $(12,752) BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING $(0.44) $(0.24) $(1.01) $(0.75) Basic and diluted weighted average number of common shares outstanding 22,719,057 17,230,559 21,351,228 16,898,040